NCT06632977RecruitingPhase 2
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) abnormalities or mutations in their cancer. Valemetostat tosylate is in a class of medications called EZH1/EZH2 inhibitors. It blocks proteins called EZH1 and EZH2, which may help slow or stop the spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Cabazitaxel injection is in a class of medications called microtubule inhibitors. It works by slowing or stopping the growth of tumor cells. Abiraterone acetate blocks tissues from making androgens (male hormones), such as testosterone. This may cause the death of tumor cells that need androgens to grow. It is a type of anti-androgen. Enzalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Lutetium Lu 177 vipivotide tetraxetan is in a class of medications called radiopharmaceuticals. It works by targeting and delivering radiation directly to tumor cells which damages and kills these cells. Assigning patients to targeted treatment based on genetic testing may help shrink or slow the cancer from growing
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 474 (estimated)
- First submitted
- 1 Oct 2024
- Start date
- 6 Feb 2025
- Primary completion date
- 11 Apr 2030
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Diseases
- Prostate cancer
- NCT number
- NCT06632977
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 474
- From 6 Feb 2025 to the primary completion date, 11 Apr 2030
- 108 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- PRE-REGISTRATION: Measurable disease and/or non-measurable metastatic disease per RECIST version 1.1.
- PRE-REGISTRATION: Tissue procured within 12 months of pre-registration (metastatic disease preferred over primary tissue, though both are acceptable) available for submission per Section 6.2. For patients who have progressed on A032102 and are pre-registering again, repeat tissue procurement will not be mandated.
- PRE-REGISTRATION: Molecular report available performed as part of standard of care testing via any Clinical Laboratory Improvement Act (CLIA)-certified next generation sequencing (NGS) assay. Patients may be assigned based on pre-determined qualifying molecular/DNA alterations as stated in Section 4.8 after receipt of local molecular testing by the A032102 molecular tumor board (MTB). Final determination of arm assignment will be determined by the MTB. For qualifying DNA alteration determined by the MTB, testing may be from tumor tissue collected at any time or circulating tumor DNA (ctDNA) within 12 months of pre-registration. If no qualifying DNA alteration is identified based on the CLIA-certified next generation sequencing assay and MTB review, Caris testing, should be performed for both DNA/RNA profiling. Arm assignment based RNA requires testing of tumor tissue collected within 12 months of pre-registration and MTB review.
- PRE-REGISTRATION: Age ≥ 18 years.
- REGISTRATION: Progressive mCRPC as defined: 1) castrate levels of serum testosterone \< 50 ng/dL AND one or more of the following criteria (choose all the apply): * PSA progression, defined by at least 2 consecutive rising PSA values at a minimum of 1-week intervals with the most recent PSA value being 2.0 ng/mL or higher, if confirmed PSA rise is the only indication of progression. Patients who received an anti-androgen must have PSA progression after withdrawal of anti-androgen therapy. * Radiographic progression per RECIST 1.1 criteria for soft tissue lesions * Bone metastasis progression per Prostate Cancer Working Group 3 (PCWG3) criteria.
- REGISTRATION: Patients selected to receive lutetium Lu 177 vipivotide tetraxetan treatment are required to have prostate-specific membrane antigen (PSMA) positive mCRPC as determined by investigator assessment. For reference, in the VISION trial this was defined as at least 1 PSMA+ metastatic lesion (defined as uptake greater than that of liver parenchyma in lesions of any size in any organ system) and no PSMA- lesions (defined as uptake equal to or lower than that of liver parenchyma in any lymph node with a short axis of at least 2.5 cm, in any solid organ lesion with a short axis of at least 1.0 cm, or in any bone lesion with a soft-tissue component of at least 1.0 cm in the short axis).
- REGISTRATION: Prior treatment with androgen receptor signaling inhibitor (ARSI) in either the metastatic hormone sensitive setting or mCRPC is required. Prior taxane therapy in either metastatic hormone sensitive setting or mCRPC is mandated unless patient is taxane ineligible or the patient refuses taxane therapy. Prior lutetium LU177 vipivotide tetraxetan treatment is permitted but not mandated. Patients with known germline or somatic deleterious BRCA 1/2 mutations must have received a prior PARPi.
- REGISTRATION: Resolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, grade ≤ 1 or baseline. Note: Subjects may be enrolled with chronic, stable grade 2 toxicities (defined as no worsening to \> grade 2 for at least 3 months prior to registration and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, comprised of: * Chemotherapy-induced neuropathy * Fatigue * Residual toxicities from prior treatment: Grade 1 or grade 2 endocrinopathies which may include: Hypothyroidism/hyperthyroidism. type I diabetes, hyperglycemia, adrenal insufficiency, adrenalitis, skin hypopigmentation (vitiligo)
- REGISTRATION: No cytotoxic, biologic, radiopharmaceutical or other non-kinase inhibitor investigational agent within 4 weeks of registration. Treatment with any type of small molecular kinase inhibitor (including investigational kinase inhibitor) within 2 weeks of registration. Treatment with abiraterone acetate, apalutamide, or darolutamide within 2 weeks of registration. Treatment with enzalutamide within 4 weeks of registration. No treatment with radiation therapy within 2 weeks of registration.
- REGISTRATION: No major surgery within 4 weeks of registration.
- REGISTRATION: No prior treatment with EZH inhibitors.
- REGISTRATION: Prior treatment with cabazitaxel + carboplatin.
- REGISTRATION: None of the following conditions: * Current use of moderate or strong cytochrome P450 (CYP)3A inducers. * Known or suspected hypersensitivity to valemetostat tosylate (DS-3201b) or any of the excipients. * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. \* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * Imminent or established spinal cord compression based on clinical and/or imaging findings. * Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to registration after radiotherapy or at least 4 weeks prior to registration after major surgery (e.g., removal or biopsy of brain metastasis). Patients must have complete wound healing from major surgery or minor surgery before registration. * Significant cardiovascular defined as: * Myocardial infarction within 6 months prior to enrollment. * Uncontrolled angina pectoris within 6 months prior to enrollment. * New York Heart Association Class 3 or 4 congestive heart failure. * Corrected QT interval calculated by the Fridericia\'s formula (QTcF) ≥ 470 ms per electrocardiogram (ECG) within 42 days before randomization in any individual with any history of any cardiac disease or medication which can impact QTcF. Patients with known history or current symptoms of cardiac disease, history of treatment with cardiotoxic agents, or agents/conditions known to impact QTcF should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification and ECG. * Uncontrolled hypertension (resting systolic blood pressure \>160 mmHg or diastolic blood pressure \> 100 mmHg). * Clinically significant acute infection requiring systemic antibacterial, antifungal or antiviral therapy. * Moderate to severe hepatic impairment (Child-Pugh Class C)
- REGISTRATION: No freezing or donating sperm ≤ 14 days prior to registration.
- REGISTRATION: Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- REGISTRATION: No granulocyte colony-stimulating factor (GCSF) within 2 weeks of registration.
- REGISTRATION: No red blood cell (RBC) transfusions within 2 weeks of registration.
- REGISTRATION: No platelet transfusions within 2 weeks of registration.
- REGISTRATION: No bleeding diathesis.
- REGISTRATION: White blood cell count (WBC) ≥ 2,500/mcL.
- REGISTRATION: Absolute neutrophil count (ANC) ≥ 1,500/mcL.
- REGISTRATION: Hemoglobin ≥ 9 g/dL.
- REGISTRATION: Platelet count ≥ 100,000/mcL.
- REGISTRATION: Creatinine clearance ≥ 30 mL/min as defined by Cockcroft-Gault equation.
- REGISTRATION: Total bilirubin ≤ 1.5 x ULN (≤ 3 x upper limit of normal \[ULN\] for subjects with documented Gilbert\'s disease).
- REGISTRATION: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN.
- REGISTRATION: Albumin ≥ 2.8 g/dL.
- REGISTRATION: The A032102 molecular tumor board will review the local pathology report and molecular sequencing report, and the Alliance registration/randomization office will relay the assignment to the submitting site. Once the site receives this assignment, they can register the patient to A032102. Any questions about the molecular board treatment assignments can be directed to.
- RE-REGISTRATION: Progressive mCRPC (after receiving the tumor board assigned therapy) as defined: 1) castrate levels of serum testosterone \< 50 ng/dL AND 2) progressive disease defined by radiographic progression on conventional imaging (CT/MRI chest, abdomen and pelvis and bone scan within 42 days of re-registration).
- RE-REGISTRATION: Resolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) resolved to CTCAE version 5.0, grade ≤ 1 or baseline. Note: Subjects may be enrolled with chronic, stable grade 2 toxicities (defined as no worsening to \> grade 2 for at least 3 months prior to registration and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, comprised of: * Chemotherapy-induced neuropathy * Fatigue * Residual toxicities from prior treatment: Grade 1 or grade 2 endocrinopathies which may include: Hypothyroidism/hyperthyroidism. type I diabetes, hyperglycemia, adrenal insufficiency, adrenalitis, skin hypopigmentation (vitiligo).
- RE-REGISTRATION: None of the following conditions: * Imminent or established spinal cord compression based on clinical and/or imaging findings. * Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to registration after radiotherapy or at least 4 weeks prior to re-registration after major surgery (e.g., removal or biopsy of brain metastasis). Patients must have complete wound healing from major surgery or minor surgery before re-registration. * Corrected QT interval calculated by the Fridericia\'s formula (QTcF) \< 470 ms per ECG within 42 days before randomization in any individual with any history of any cardiac disease or medication which can impact QTcF. * Significant cardiovascular defined as: * Myocardial infarction within 6 months prior to enrollment. * Uncontrolled angina pectoris within 6 months prior to enrollment. * New York Heart Association Class 3 or 4 congestive heart failure. * Uncontrolled hypertension (resting systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg).
- RE-REGISTRATION: ECOG Performance Status 0-2.
- RE-REGISTRATION: No GCSF within 2 weeks of registration.
- RE-REGISTRATION: No RBC transfusions within 2 weeks of registration.
- RE-REGISTRATION: No platelet transfusions within 2 weeks of registration.
- RE-REGISTRATION: WBC ≥ 2,500/mcL.
- RE-REGISTRATION: ANC ≥ 1,500/mcL.
- RE-REGISTRATION: Hemoglobin ≥ 9 g/dL (transfusions permitted).
- RE-REGISTRATION: Platelet count ≥ 100,000/mcL.
- RE-REGISTRATION: Creatinine clearance ≥ 30 mL/min as defined by Cockcroft-Gault equation.
- RE-REGISTRATION: Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for subjects with documented Gilbert\'s disease).
- RE-REGISTRATION: AST and ALT ≤ 3 x ULN.
- RE-REGISTRATION: Albumin ≥ 2.8 g/dL.
- RE-REGISTRATION: QT Interval (QTcF) \< 470 ms (in individuals with any cardiac history of any medication or condition known to impact QTcF).
- RE-REGISTRATION: The A032102 molecular tumor board will review the CARIS molecular sequencing report, the Alliance registration/randomization office will relay the assignment to the site. Any questions about the molecular board treatment assignments can be directed to. Exclusion Criteria: \-
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (108)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| McFarland Clinic - Ames Coordinator of this site? Confirm its status | Ames | United States | Recruiting |
| University of Iowa Healthcare Cancer Services Quad Cities Coordinator of this site? Confirm its status | Bettendorf | United States | Recruiting |
| Billings Clinic Cancer Center Coordinator of this site? Confirm its status | Billings | United States | Recruiting |
| University of Alabama at Birmingham Cancer Center Coordinator of this site? Confirm its status | Birmingham | United States | Recruiting |
| Illinois CancerCare-Bloomington Coordinator of this site? Confirm its status | Bloomington | United States | Recruiting |
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Suspended |
| Essentia Health Saint Joseph's Medical Center Coordinator of this site? Confirm its status | Brainerd | United States | Recruiting |
| Trinity Health IHA Medical Group Hematology Oncology - Brighton Coordinator of this site? Confirm its status | Brighton | United States | Recruiting |
| Roswell Park Cancer Institute Coordinator of this site? Confirm its status | Buffalo | United States | Recruiting |
| Trinity Health IHA Medical Group Hematology Oncology - Canton Coordinator of this site? Confirm its status | Canton | United States | Recruiting |
| Illinois CancerCare-Canton Coordinator of this site? Confirm its status | Canton | United States | Recruiting |
| UNC Lineberger Comprehensive Cancer Center Coordinator of this site? Confirm its status | Chapel Hill | United States | Recruiting |
| Vandalia Health/CAMC Institute for Academic Medicine Coordinator of this site? Confirm its status | Charleston | United States | Active, not recruiting |
| Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Coordinator of this site? Confirm its status | Chelsea | United States | Recruiting |
| Enloe Medical Center Coordinator of this site? Confirm its status | Chico | United States | Recruiting |
| Siteman Cancer Center at Saint Peters Hospital Coordinator of this site? Confirm its status | City of Saint Peters | United States | Recruiting |
| MetroHealth Medical Center Coordinator of this site? Confirm its status | Cleveland | United States | Recruiting |
| Kootenai Health - Coeur d'Alene Coordinator of this site? Confirm its status | Coeur d'Alene | United States | Suspended |
| Memorial Hospital North Coordinator of this site? Confirm its status | Colorado Springs | United States | Recruiting |
| UCHealth Memorial Hospital Central Coordinator of this site? Confirm its status | Colorado Springs | United States | Recruiting |
| MU Health - University Hospital/Ellis Fischel Cancer Center Coordinator of this site? Confirm its status | Columbia | United States | Active, not recruiting |
| Ohio State University Comprehensive Cancer Center Coordinator of this site? Confirm its status | Columbus | United States | Recruiting |
| Siteman Cancer Center at West County Hospital Coordinator of this site? Confirm its status | Creve Coeur | United States | Recruiting |
| UT Southwestern Simmons Cancer Center - RedBird Coordinator of this site? Confirm its status | Dallas | United States | Recruiting |
| Parkland Memorial Hospital Coordinator of this site? Confirm its status | Dallas | United States | Suspended |
| UT Southwestern/Simmons Cancer Center-Dallas Coordinator of this site? Confirm its status | Dallas | United States | Recruiting |
| Carle at The Riverfront Coordinator of this site? Confirm its status | Danville | United States | Recruiting |
| Essentia Health Cancer Center Coordinator of this site? Confirm its status | Duluth | United States | Recruiting |
| Saint Elizabeth Healthcare Edgewood Coordinator of this site? Confirm its status | Edgewood | United States | Recruiting |
| Swedish Cancer Institute-Edmonds Coordinator of this site? Confirm its status | Edmonds | United States | Recruiting |
| Carle Physician Group-Effingham Coordinator of this site? Confirm its status | Effingham | United States | Recruiting |
| UC San Diego Health System - Encinitas Coordinator of this site? Confirm its status | Encinitas | United States | Recruiting |
| Illinois CancerCare-Eureka Coordinator of this site? Confirm its status | Eureka | United States | Recruiting |
| Essentia Health Cancer Center-South University Clinic Coordinator of this site? Confirm its status | Fargo | United States | Recruiting |
| Poudre Valley Hospital Coordinator of this site? Confirm its status | Fort Collins | United States | Recruiting |
| Cancer Care and Hematology-Fort Collins Coordinator of this site? Confirm its status | Fort Collins | United States | Recruiting |
| Saint Elizabeth Healthcare Fort Thomas Coordinator of this site? Confirm its status | Fort Thomas | United States | Suspended |
| UT Southwestern/Simmons Cancer Center-Fort Worth Coordinator of this site? Confirm its status | Fort Worth | United States | Recruiting |
| Dana-Farber Cancer Institute at Foxborough Coordinator of this site? Confirm its status | Foxborough | United States | Recruiting |
| Gibbs Cancer Center-Gaffney Coordinator of this site? Confirm its status | Gaffney | United States | Recruiting |
| UCHealth Greeley Hospital Coordinator of this site? Confirm its status | Greeley | United States | Recruiting |
| Gibbs Cancer Center-Pelham Coordinator of this site? Confirm its status | Greer | United States | Recruiting |
| Hackensack University Medical Center Coordinator of this site? Confirm its status | Hackensack | United States | Recruiting |
| Tripler Army Medical Center Coordinator of this site? Confirm its status | Honolulu | United States | Recruiting |
| Edwards Comprehensive Cancer Center Coordinator of this site? Confirm its status | Huntington | United States | Recruiting |
| University of Iowa/Holden Comprehensive Cancer Center Coordinator of this site? Confirm its status | Iowa City | United States | Recruiting |
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Coordinator of this site? Confirm its status | Irvine | United States | Active, not recruiting |
| Jupiter Medical Center Coordinator of this site? Confirm its status | Jupiter | United States | Recruiting |
| University of Kansas Cancer Center Coordinator of this site? Confirm its status | Kansas City | United States | Recruiting |
| UC San Diego Moores Cancer Center Coordinator of this site? Confirm its status | La Jolla | United States | Recruiting |
| University of Michigan Health - Sparrow Lansing Coordinator of this site? Confirm its status | Lansing | United States | Recruiting |
| Trinity Health Saint Mary Mercy Livonia Hospital Coordinator of this site? Confirm its status | Livonia | United States | Recruiting |
| Medical Center of the Rockies Coordinator of this site? Confirm its status | Loveland | United States | Recruiting |
| Marshfield Medical Center-Marshfield Coordinator of this site? Confirm its status | Marshfield | United States | Recruiting |
| Carle Physician Group-Mattoon/Charleston Coordinator of this site? Confirm its status | Mattoon | United States | Recruiting |
| Bon Secours Memorial Regional Medical Center Coordinator of this site? Confirm its status | Mechanicsville | United States | Recruiting |
| Froedtert Menomonee Falls Hospital Coordinator of this site? Confirm its status | Menomonee Falls | United States | Recruiting |
| Dana Farber-Merrimack Valley Coordinator of this site? Confirm its status | Methuen | United States | Recruiting |
| Bon Secours Saint Francis Medical Center Coordinator of this site? Confirm its status | Midlothian | United States | Recruiting |
| Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Coordinator of this site? Confirm its status | Milford | United States | Recruiting |
| Beebe South Coastal Health Campus Coordinator of this site? Confirm its status | Millville | United States | Recruiting |
| Medical College of Wisconsin Coordinator of this site? Confirm its status | Milwaukee | United States | Recruiting |
| Vanderbilt University/Ingram Cancer Center Coordinator of this site? Confirm its status | Nashville | United States | Suspended |
| Medical Oncology Hematology Consultants PA Coordinator of this site? Confirm its status | Newark | United States | Recruiting |
| Helen F Graham Cancer Center Coordinator of this site? Confirm its status | Newark | United States | Recruiting |
| Mount Sinai Hospital Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| Drexel Town Square Health Center Coordinator of this site? Confirm its status | Oak Creek | United States | Recruiting |
| Cancer Care Center of O'Fallon Coordinator of this site? Confirm its status | O'Fallon | United States | Recruiting |
| University of Oklahoma Health Sciences Center Coordinator of this site? Confirm its status | Oklahoma City | United States | Recruiting |
| The University of Kansas Cancer Center - Olathe Coordinator of this site? Confirm its status | Olathe | United States | Recruiting |
| UC Irvine Health- Chao Family Comprehensive Cancer Center Coordinator of this site? Confirm its status | Orange | United States | Active, not recruiting |
| Illinois CancerCare-Ottawa Clinic Coordinator of this site? Confirm its status | Ottawa | United States | Recruiting |
| University of Kansas Hospital-Indian Creek Campus Coordinator of this site? Confirm its status | Overland Park | United States | Recruiting |
| Illinois CancerCare-Pekin Coordinator of this site? Confirm its status | Pekin | United States | Recruiting |
| Illinois CancerCare-Peoria Coordinator of this site? Confirm its status | Peoria | United States | Recruiting |
| Illinois CancerCare-Peru Coordinator of this site? Confirm its status | Peru | United States | Recruiting |
| Providence Saint Vincent Medical Center Coordinator of this site? Confirm its status | Portland | United States | Recruiting |
| Providence Portland Medical Center Coordinator of this site? Confirm its status | Portland | United States | Recruiting |
| Oregon Health and Science University Coordinator of this site? Confirm its status | Portland | United States | Recruiting |
| Beebe Health Campus Coordinator of this site? Confirm its status | Rehoboth Beach | United States | Recruiting |
| UT Southwestern Clinical Center at Richardson/Plano Coordinator of this site? Confirm its status | Richardson | United States | Recruiting |
| VCU Massey Comprehensive Cancer Center Coordinator of this site? Confirm its status | Richmond | United States | Recruiting |
| Bon Secours Richmond Community Hospital Coordinator of this site? Confirm its status | Richmond | United States | Recruiting |
| Bon Secours Cancer Institute at Reynolds Crossing Coordinator of this site? Confirm its status | Richmond | United States | Recruiting |
| VCU Massey Cancer Center at Stony Point Coordinator of this site? Confirm its status | Richmond | United States | Recruiting |
| Bon Secours Saint Mary's Hospital Coordinator of this site? Confirm its status | Richmond | United States | Recruiting |
| University of California Davis Comprehensive Cancer Center Coordinator of this site? Confirm its status | Sacramento | United States | Recruiting |
| Coborn Cancer Center at Saint Cloud Hospital Coordinator of this site? Confirm its status | Saint Cloud | United States | Recruiting |
| UC San Diego Medical Center - Hillcrest Coordinator of this site? Confirm its status | San Diego | United States | Recruiting |
| Guthrie Medical Group PC-Robert Packer Hospital Coordinator of this site? Confirm its status | Sayre | United States | Active, not recruiting |
| Swedish Medical Center-First Hill Coordinator of this site? Confirm its status | Seattle | United States | Recruiting |
| Memorial Hospital East Coordinator of this site? Confirm its status | Shiloh | United States | Recruiting |
| Dana-Farber/Brigham and Women's Cancer Center at South Shore Coordinator of this site? Confirm its status | South Weymouth | United States | Recruiting |
| Spartanburg Medical Center Coordinator of this site? Confirm its status | Spartanburg | United States | Recruiting |
| Baystate Medical Center Coordinator of this site? Confirm its status | Springfield | United States | Recruiting |
| Stamford Hospital/Bennett Cancer Center Coordinator of this site? Confirm its status | Stamford | United States | Recruiting |
| Washington University School of Medicine Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
| Siteman Cancer Center at Christian Hospital Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
| Siteman Cancer Center-South County Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
| University of Kansas Health System Saint Francis Campus Coordinator of this site? Confirm its status | Topeka | United States | Recruiting |
| Banner University Medical Center - Tucson Coordinator of this site? Confirm its status | Tucson | United States | Recruiting |
| University of Arizona Cancer Center-North Campus Coordinator of this site? Confirm its status | Tucson | United States | Recruiting |
| SMC Center for Hematology Oncology Union Coordinator of this site? Confirm its status | Union | United States | Recruiting |
| Carle Cancer Center Coordinator of this site? Confirm its status | Urbana | United States | Recruiting |
| Illinois CancerCare - Washington Coordinator of this site? Confirm its status | Washington | United States | Recruiting |
| Froedtert West Bend Hospital/Kraemer Cancer Center Coordinator of this site? Confirm its status | West Bend | United States | Recruiting |
| University of Kansas Hospital-Westwood Cancer Center Coordinator of this site? Confirm its status | Westwood | United States | Recruiting |
| Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Coordinator of this site? Confirm its status | Ypsilanti | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.